Cellply, a Bologna, Italy-based biotech company providing an end-to-end single cell potency characterization platform, raised €3.6M in funding.
The round was led by Recomec, Liftt, and Schia Ventures.
The company intends to use the funds to expand operations and its development efforts.
Founded in 2013 by Massimo Bocchi and Roberto Guerrieri, led by CEO Emiliano Spagnolo, CellPly is a life-science company developing analytical tools for the immune system and enabling rapid and effective development of immunotherapies and cell-based therapies. Its solution combines proprietary microfluidic technology to capture functional and phenotypic information from thousands of single cells, with the automated VivaCyte® analytical instrument, integrating robotic solutions and AI for image analysis.
Short-term objectives include consolidating the research and development market, entering the U.S. market and establishing Cellply North America, while strengthening its presence in the European market. In the long term, the goal is to become the leader in analytical tools for research and quality control within the “Cell Therapy” sector.
FinSMEs
02/10/2023